Tuesday, September 15, 2026
spot_img

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company’s Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) in connection with Mr. Kohl’s previously announced appointment as Chief Executive Officer and President of the Company effective on September 14, 2026. The awards were granted as inducement material to Mr. Kohl’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Of the 2,747,385 RSUs granted to Mr. Kohl, 915,975 RSUs will vest on September 14, 2027 and the remaining RSUs will vest in eight approximately equal quarterly installments, in each case subject to Mr. Kohl’s continued employment with the Company on such vesting date. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company or its subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

On September 11, 2026 and September 14, 2026, Mr. Kohl acquired an aggregate of 59,000 shares of Health Catalyst’s common stock through open market purchases with a weighted average price of $1.787188 per share.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Health Catalyst Investor Relations Contact
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
[email protected]

Health Catalyst Media Contact
Kay Blazar
VP, PR
SVM PR & Marketing
[email protected]

Powered by SlickText.com

Hot this week

Questor Announces Resignation of Chief Financial Officer

CALGARY, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) --...

Five Star Bancorp Deepens Community Commitment with Appointment of Lydia Ramirez as Chief External Affairs Officer

New executive role places dedicated expertise behind Five Star...

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

- All rights to TransCon technology-based products in metabolic...

Ascendis Announces Planned $400 Million Share Repurchase Program

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) --...

Topics

Questor Announces Resignation of Chief Financial Officer

CALGARY, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) --...

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

- All rights to TransCon technology-based products in metabolic...

Ascendis Announces Planned $400 Million Share Repurchase Program

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) --...

Disclosure of treasury shares transactions carried out from September 9 to September 11, 2026

 Disclosure of treasury shares transactions carried out from September...

The Children’s Place Reports Second Quarter 2026 Results

Opened 19 new stores during the quarter Significant decrease in...

DLH Appoints Brooke Pierce President of Health Business Group

ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- DLH...
spot_img

Related Articles

Popular Categories

spot_img